Miraqules
PrivateLast Round
Accelerator
Jul 10, 2023
Est. Valuation
$1.8M
Total Funding Raised
$492,000
Momentum Score
50 /100
Company Overview
Miraqules is a biomedical startup that develops and manufactures anti-bleeding solutions designed for the rapid control of hemorrhage. Founded in 2018, the company's flagship product is 'StopBleed,' a patented nano-biopolymer hemostat that mimics the body's natural clotting process to stop bleeding in seconds. The technology was developed to be a more effective and affordable alternative to existing hemostats, with applications ranging from first-aid and emergency response to surgical settings. Miraqules operates on a business-to-business (B2B) and business-to-government (B2G) model, aiming to make its life-saving technology widely accessible. The company was founded by Sabir Hossain, Dr. Mubeen Midda, and Dr. Devendra Verma.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Advanced Materials, Defense Tech
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Miraqules Comps
Public and private peers based on sector, stage, and business model.
Miraqules Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Jul 10, 2023 | ||||
| Early Funding | Mar 31, 2022 | ||||
| Grant | Oct 20, 2021 | ||||
| Grant | Jan 1, 2020 | ||||
| Grant | Oct 15, 2019 | ||||
Grant | Jul 31, 2019 |
Key People
Founding team and executive leadership
Miraqules Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Biotechnology Industry Research Assistance Council | Grant |
| Defence Research and Development Organisation (DRDO) | Grant |
| MedTech Innovator | Grant |
| MassChallenge | Grant |
| GoAhead Ventures | Early Funding |
| KIIT-Technology Business Incubator | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 27, 2025
Will showcase blood clotting technology at TechCrunch Disrupt 2025.
Miraqules Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Miraqules's valuation, stock price, and market status.
